SAINT PAUL, Minn., March 5, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today reported financial results for the first quarter fiscal 2013 ended January 31, 2013.
First Quarter Highlights:
First quarter fiscal 2013 total revenues increased 9% to $7.0 million compared to $6.4 million in the fiscal 2012 first quarter. Domestic 2013 first quarter sales were $5.3 million, compared to $5.0 million in the 2012 first quarter, while international sales were $1.7 million, versus $1.4 million in last year's first quarter. For the first quarter, Group Purchasing Organization ("GPO") sales increased 109% to $3.2 million, as compared to $1.5 million in the prior year's first quarter. GPO sales accounted for approximately 46% of total sales for the 2013 first quarter, compared to 24% in the 2012 first quarter.
First quarter equipment, supplies and accessories sales totaled $5.8 million, compared to $5.4 million during last year's first quarter. Service revenues for the first quarter totaled $1.2 million, compared to $1.1 million during last year's first quarter. The Attachment Rate, which reflects the percentage of Extended Service Contracts added at the point of sale to customer equipment purchases, was 17% for the first quarter of fiscal 2013. The attachment rate has steadily increased from the low single-digit level when the current management team was installed. The Company's "Real Time Diffusion" ("RTD") technology continues to do well, with 79% of new pulmonary device equipment sales during the quarter containing RTD capabilities.
Gross margin for the quarter was 54.5% compared to 55.5% in the 2012 first quarter. Gross margin for equipment, supplies and accessories fell to 51.2% for the quarter, compared to 53.0% in the prior year's quarter, primarily as a result of product mix. Gross margin for services increased to 70.8% for the quarter, compared to 68.4% for the prior year's quarter primarily as a result of improved pricing.
First quarter 2013 general and administrative expenses totaled $1.4 million versus $1.1 million in the comparable quarter last year. Sales and marketing expenses were $2.1 million compared to $1.8 million in the 2012 first quarter.
For the 2013 first quarter, the Company reported a net loss of $383,000, or ($0.10) per diluted share, versus a net loss of $249,000, or ($0.07) per diluted share, in the 2012 first quarter. During the quarter, the Company incurred non-recurring corporate development expenses of approximately $177,000 while pursuing a potential strategic acquisition. The Company abandoned the acquisition during the later stages of due diligence. The Company also incurred a $28,000 expense related to legal fees regarding an intellectual property dispute. Research and development expenses were $647,000 compared to $810,000 in last year's first quarter, reflecting cost savings from prior year executive separations and conversion of consulting resources to full time personnel.
Gregg O. Lehman, Ph D., president and chief executive officer of MGC Diagnostics, said, "We are very pleased with the revenue increase achieved in the fiscal 2013 first quarter. The nine percent increase is the highest first quarter revenue increase in nearly a decade. With the implementation of a new strategic initiative to drive improved first quarter sales, our sales force did a great job of converting sales leads into active buyers."
"We had solid performance across all of our sales channels and geographies. During the quarter, revenue from our GPO distribution channel increased 109%. International sales were up 25%, as we made a number of upgrades in our international distribution group. Extended service contracts sold at the point of sale increased to 17% compared to 7% in Q1 2012. Recurring revenue, which includes supply and service revenue, totaled 39% of total first quarter revenue. Growing our base of recurring revenue, which provides our highest gross margin, will continue to be a core focus. We are off to a good start in fiscal 2013 and we look forward to the rest of the year."
Dr. Lehman continued, "In January 2013, Denver-based National Jewish Health, known worldwide for treatment of patients with respiratory, cardiac, immune and related disorders, and for groundbreaking medical research, selected MGC Diagnostics as its preferred provider of cardiopulmonary diagnostic technology and equipment. We are proud that an internationally renowned institution the caliber of National Jewish has selected our technology as its preferred option. This was an important competitive win for MGC Diagnostics and marks an important point in the Company's history as we transition into a leading innovator and aggressive sales and marketing organization. I believe this sets the stage for MGC Diagnostics to attract other leading cardiorespiratory institutions to partner with us. We firmly believe there are other significant opportunities in 2013 and beyond."
On August 28, 2012, the Company completed the sale of the assets of its New Leaf business to Life Time Fitness, Inc. for $1.235 million. As a result, the Company has reclassified its results for prior periods to eliminate from its statement of comprehensive loss all fiscal 2012 revenues and expenses associated with its New Leaf business and presented the income (loss) from New Leaf activities as "discontinued operations."
Net Operating Loss Carry Forward
At January 31, 2013, the Company had federal net operating loss carry forwards of approximately $14.5 million, not subject to IRC annual limitations on use. These loss carry forwards will expire in years 2018 through 2032.
The Company has scheduled a conference call for Tuesday, March 5, 2013 at 4:30 p.m. ET to discuss its financial results for the first quarter of fiscal year 2013.
Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or listen via a live Internet webcast on the Company's website at www.mgcdiagnostics.com. A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10025649, through March 12, 2013. A webcast replay of the conference call will be accessible on the Company's website at www.mgcdiagnostics.com for 90 days.
About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.
Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:
Wesley W. Winnekins
Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics Corporation
Lytham Partners, LLCChief Financial Officer
(602) 889-9700(651) 484-4874
email@example.com(Financial Tables to Follow)
MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Balance Sheets(In thousands, except share and per share data) January 31, October 31, 20132012Assets(Unaudited)Current Assets:Cash and cash equivalents$
9,665Accounts receivable, net of allowance for doubtful accounts of $105 and $98, respectively6,0295,860Inventories, net of obsolescence reserve of $394 and $373, respectively4,0363,850Prepaid expenses and other current assets298418Total current assets19,28519,793Property and equipment, net of accumulated depreciation of $3,925 and $3,876, respectively 753578Intangible assets, net1,7711,492Other non-current assets8585Total Assets$
21,948Liabilities and Shareholders' EquityCurrent Liabilities:Accounts payable $
2,094Employee compensation1,4931,749Deferred income1,9941,927Warranty reserve8491Other current liabilities and accrued expenses509442Total current liabilities6,0866,303Long-term liabilities:Long-term deferred income and other1,300895Total Liabilities7,3867,198Commitments and ContingenciesShareholders' Equity:Common stock, $0.10 par value, authorized 25,000,000 shares, 4,000,678 and 3,986,350 shares issued and 3,901,607 and 3,885,279 shares outstanding in 2013 and 2012, respectively390388Undesignated shares, authorized 5,000,000 shares, no shares issued and outstanding--Additional paid-in capital21,18521,046Accumulated deficit(7,067)(6,684)Total Shareholders' Equity14,50814,750Total Liabilities and Shareholders' Equity$
21,948 MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Statements of Comprehensive Loss(Unaudited in thousands, except per share amounts)Three Months Ended
January 31,20132012RevenuesEquipment, supplies and accessories revenues$
5,372Service revenues1,2021,0567,0086,428Cost of revenuesCost of equipment, supplies and accessories revenues2,8352,525Cost of service revenues3513343,1862,859Gross margin3,8223,569Operating expenses:Selling and marketing2,1261,775General and administrative1,4181,145Research and development647810Amortization of intangibles71084,1983,838Operating loss(376)(269)Interest income-4Loss from continuing operations before taxes(376)(265)Provision for taxes77Loss from continuing operations(383)(272)Discontinued operationsIncome from operations of discontinued operations-23Net loss(383)(249)Other comprehensive loss; net of taxUnrealized loss on securities-(1)Comprehensive loss$
(250)Loss per shareBasicFrom continuing operations$
(0.07)From discontinued operations0.000.00Total$
(0.07)DilutedFrom continuing operations$
(0.07)From discontinued operations0.000.00Total$
(0.07)Weighted average common shares outstandingBasic3,8913,780Diluted3,8913,780 MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Statements of Cash Flows(Unaudited in thousands)Three Months Ended
January 31,20132012Cash flows from operating activities:Net loss$
(249)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation5564Amortization21108Stock-based compensation101137Increase (decrease) in allowance for doubtful accounts7(3)Decrease in inventory obsolescence reserve2147Gain on disposal of equipment(3)-Changes in operating assets and liabilities:Accounts receivable(176)1,063Inventories(207)(419)Prepaid expenses and other current assets12037Accounts payable(88)(189)Employee compensation(256)(202)Deferred income314(218)Warranty reserve(7)(19)Other current liabilities and accrued expenses(3)9Net cash (used in) provided by operating activities(484)166Cash flows from investing activities:Sales of investments-241Purchases of property and equipment and intangible assets(317)(240)Net cash (used in) provided by investing activities(317)1Cash flows from financing activities:Proceeds from issuance of common stock under employee stock purchase plan6811Proceeds from the exercise of stock options-40Repurchase of common stock-(5)Repurchase of common stock upon vesting of restricted stock awards(10)-Net cash provided by financing activities5846Net increase in cash and cash equivalents(743)213Cash and cash equivalents at beginning of year9,6658,461Cash and cash equivalents at end of year$
8,674Cash paid for taxes$$
2Supplemental non-cash items:Current and non-current liabilities issued for leasehold improvements$
|SOURCE MGC Diagnostics Corporation|
Copyright©2012 PR Newswire.
All rights reserved